Xeris Biopharma Holdings, Inc. (XERS) Cash Flow Statement
Xeris Biopharma Holdings, Inc. (XERS) generated $56.6M of operating cash flow over the twelve months to 2026-06-30, spent $938000 on capital expenditure and had free cash flow of $55.7M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
XERSXeris Biopharma Holdings, Inc.Follow XERS — free
—
Price chart with a free account
- Market cap
- 1.9B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -95.5 | -102.9 | -47.0 | -37.0 | 28.6 | 56.6 | |
| Capital expenditure | 1.1 | 0.5 | 2.3 | 0.9 | 0.7 | -0.9 | |
| Free cash flow | -96.6 | -103.4 | -49.3 | -37.8 | 27.9 | 55.7 | |
| Stock-based compensation | 11.4 | 12.2 | 10.7 | 18.4 | 22.4 | — |
USD millions · SEC XBRL
Xeris Biopharma Holdings, Inc. — questions
- What is Xeris Biopharma Holdings, Inc.'s operating cash flow?
- $56.6M over the twelve months to 2026-06-30.
- How much does Xeris Biopharma Holdings, Inc. spend on capital expenditure?
- $938000 over the twelve months to 2026-06-30.
- What is Xeris Biopharma Holdings, Inc.'s free cash flow?
- $55.7M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Xeris Biopharma Holdings, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.